Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer

Pancreatic cancer is a fatal cancer. Most patients are being diagnosed as in a progressive phase of progress. Despite improvements in diagnostic methods and management strategies, including surgical methods and chemotherapy, pancreatic cancer results are still bad. Ultrasound endoscopy (EUS) is an important imaging tool for pancreatic cancer. Resected pancreatic cancer and other cancer specimens have been used for decades to identify tissue biomarkers or genomics for accurate treatment; however, only 20% of patients have surgery. Cancer is ineffective. As needle technology advances, tumor specimens can be obtained at the time of tissue diagnosis. Tumor tissue can be used for the development of individualized cancer therapies such as full-exosome sequencing and global genome analysis of pancreatic cancer, development of tissue biomarkers, targeted mutation assays for fine chemotherapy . This review will explain the latest advances in the acquisition of pancreatic cancer tissue. View full text

This is an open access article distributed under the Creative Commons Attribution License, allowing unrestricted use, distribution, and copying on any media as long as the original work is appropriately referenced (CC BY 0)

EUS-induced FNA (EUS-FNA) is an established technique for tissue acquisition of solid pancreatic disease. Cytologic specimens obtained by fine needle aspiration (FNA) can diagnose malignant tumors, but it is important to obtain large tissue cores such as autoimmune pancreatitis, lymphoma and gastrointestinal stromal tumor. In addition, more core organizations are available for Next Generation Sequencing (NGS) for personalized medicine in PDAC. Due to flexibility and technical difficulty, a 19 gauge FNA needle is typically not used in clinical practice for core tissue collection. Recently developed micro biopsy forceps enable EUS guide under needle biopsy (EUS - TTNFB). Previously reported procaine model studies provided potential utility for solid pancreatic lesions. A median of 3 passes per pass, a total of 49 passes was done. No report of pancreatitis

Advances in EUS in tissue collection have increased expectations in the field of precision therapy through the combination of development of organs and biomarkers, drug testing and discovery, total exosome sequencing, and early detection of free-circulating DNA. These developments will give us the opportunity to understand individual tumor biology and bring about fields closer to personalized medicine.

In a recent study, ultrasound endoscopy (EUS) assessment of pancreatic cancer was considered an independent predictor of survival and improvement in patients with focal pancreatic cancer. We will focus on all aspects of the role of EUS in the treatment of pancreatic cancer.

Cancer belonging to pancreatic tissue is called pancreatic cancer and is based on two cell types called exocrine pancreatic cancer and endocrine pancreatic cancer. Pancreatic exocrine cancer is often observed in pancreatic cells rather than other types. Exocrine tumors are characterized in that they do not secrete hormones and do not even show signs or symptoms. This in turn makes it difficult to diagnose this type of pancreatic cancer and current therapies do not cure cancer. Pancreatic cancer usually spreads rapidly and is rarely discovered at an early stage, which is the main cause of cancer death. Cancer detection and stage can be detected by pancreatic cancer screening. Certain types of malignant pancreatic neuroendocrine tumors such as pancreatic islet cell tumors have a better prognosis than pancreatic exocrine cancer